Zhejiang Medicine Co Ltd (600216) - Total Liabilities
Based on the latest financial reports, Zhejiang Medicine Co Ltd (600216) has total liabilities worth CN¥2.81 Billion CNY (≈ $411.69 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600216 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Zhejiang Medicine Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Zhejiang Medicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Zhejiang Medicine Co Ltd.
Zhejiang Medicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Medicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Port Co Ltd
SHG:600717
|
China | CN¥8.84 Billion |
|
Zydus Wellness Limited
NSE:ZYDUSWELL
|
India | Rs41.76 Billion |
|
OVH Groupe SAS
PA:OVH
|
France | €1.73 Billion |
|
Dime Community Bancshares, Inc.
NYSE:DCOM
|
USA | $13.49 Billion |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
USA | $77.20 Million |
|
Woolworths Holdings Ltd
JSE:WHL
|
South Africa | ZAC30.14 Billion |
|
Guangdong Rongtai Industry Co Ltd
SHG:600589
|
China | CN¥3.49 Billion |
|
National Bank Holdings Corporation
NYSE:NBHC
|
USA | $10.92 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Zhejiang Medicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Zhejiang Medicine Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Medicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Medicine Co Ltd (1997–2025)
The table below shows the annual total liabilities of Zhejiang Medicine Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.00 Billion ≈ $439.23 Million |
+2.53% |
| 2024-12-31 | CN¥2.93 Billion ≈ $428.39 Million |
+4.81% |
| 2023-12-31 | CN¥2.79 Billion ≈ $408.73 Million |
+2.59% |
| 2022-12-31 | CN¥2.72 Billion ≈ $398.42 Million |
-18.72% |
| 2021-12-31 | CN¥3.35 Billion ≈ $490.20 Million |
+35.60% |
| 2020-12-31 | CN¥2.47 Billion ≈ $361.50 Million |
+17.07% |
| 2019-12-31 | CN¥2.11 Billion ≈ $308.78 Million |
+7.45% |
| 2018-12-31 | CN¥1.96 Billion ≈ $287.37 Million |
-2.50% |
| 2017-12-31 | CN¥2.01 Billion ≈ $294.75 Million |
+10.52% |
| 2016-12-31 | CN¥1.82 Billion ≈ $266.69 Million |
+11.56% |
| 2015-12-31 | CN¥1.63 Billion ≈ $239.06 Million |
+24.93% |
| 2014-12-31 | CN¥1.31 Billion ≈ $191.36 Million |
+21.54% |
| 2013-12-31 | CN¥1.08 Billion ≈ $157.44 Million |
+25.00% |
| 2012-12-31 | CN¥860.73 Million ≈ $125.95 Million |
+7.78% |
| 2011-12-31 | CN¥798.63 Million ≈ $116.86 Million |
+3.20% |
| 2010-12-31 | CN¥773.86 Million ≈ $113.24 Million |
-24.01% |
| 2009-12-31 | CN¥1.02 Billion ≈ $149.01 Million |
-29.86% |
| 2008-12-31 | CN¥1.45 Billion ≈ $212.46 Million |
-26.33% |
| 2007-12-31 | CN¥1.97 Billion ≈ $288.39 Million |
+12.55% |
| 2006-12-31 | CN¥1.75 Billion ≈ $256.24 Million |
+18.67% |
| 2005-12-31 | CN¥1.48 Billion ≈ $215.92 Million |
+23.66% |
| 2004-12-31 | CN¥1.19 Billion ≈ $174.61 Million |
+14.70% |
| 2003-12-31 | CN¥1.04 Billion ≈ $152.23 Million |
+3.31% |
| 2002-12-31 | CN¥1.01 Billion ≈ $147.35 Million |
+5.26% |
| 2001-12-31 | CN¥956.66 Million ≈ $139.99 Million |
+19.34% |
| 2000-12-31 | CN¥801.61 Million ≈ $117.30 Million |
-26.81% |
| 1999-12-31 | CN¥1.10 Billion ≈ $160.27 Million |
+39.90% |
| 1998-12-31 | CN¥782.87 Million ≈ $114.56 Million |
+21.91% |
| 1997-12-31 | CN¥642.18 Million ≈ $93.97 Million |
-- |
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well… Read more